日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

When is a sample a urine sample? Markers for urine sample authenticity assessment in sports drug testing

什么情况下样本才算是尿液样本?运动药物检测中尿液样本真实性评估的标志物

Piper, T; Geyer, H; Huelsemann, F; Mareck, U; Walpurgis, K; Fusshoeller, G; Thomas, A; Thevis, M

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial

乳腺癌指数和辅助他莫昔芬治疗乳腺癌患者从延长内分泌治疗中获益的预测——aTTom试验

Bartlett, J M S; Sgroi, D C; Treuner, K; Zhang, Y; Ahmed, I; Piper, T; Salunga, R; Brachtel, E F; Pirrie, S J; Schnabel, C A; Rea, D W

Evaluative Thinking in Practice: The National Asthma Control Program

评估性思维的实践:国家哮喘控制计划

Fierro, Leslie A; Codd, Heather; Gill, Sarah; Pham, Phung K; Grandjean Targos, Piper T; Wilce, Maureen

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial

计算病理学测定的淋巴细胞密度被证实可预测乳腺癌新辅助化疗的疗效:ARTemis试验的二次分析

Ali, H R; Dariush, A; Thomas, J; Provenzano, E; Dunn, J; Hiller, L; Vallier, A-L; Abraham, J; Piper, T; Bartlett, J M S; Cameron, D A; Hayward, L; Brenton, J D; Pharoah, P D P; Irwin, M J; Walton, N A; Earl, H M; Caldas, C

The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer

BIG 2.04 MRC/EORTC SUPREMO 试验:一项大型 3 期随机国际临床试验(针对中危乳腺癌患者进行乳房切除术后放疗)的病理质量保证

Thomas, J S; Hanby, A M; Russell, N; van Tienhoven, G; Riddle, K; Anderson, N; Cameron, D A; Bartlett, J M S; Piper, T; Cunningham, C; Canney, P; Kunkler, I H

Firearm suicide in New York City in the 1990s

20世纪90年代纽约市的枪支自杀事件

Piper, T M; Tracy, M; Bucciarelli, A; Tardiff, K; Galea, S